Sec Form 4 Filing - Reichman Amir @ Scinai Immunotherapeutics Ltd. - 2026-06-16

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Reichman Amir 2. Issuer Name and Ticker or Trading Symbol Scinai Immunotherapeutics Ltd. [ SCNI] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Executive Officer (Last) (First) (Middle) C/O SCINAI IMMUNOTHERAPEUTICS LTD., JERUSALEM BIOPARK, 2ND FLOOR 3. Date of Earliest Transaction (MM/DD/YY) 06/16/2026 (Street) JERUSALEM9112002 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Ordinary Shares ( 1 ) 06/16/2026 A 400,000,000 ( 2 ) A $ 0 711,637,600 ( 3 ) ( 4 ) D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Reichman Amir C/O SCINAI IMMUNOTHERAPEUTICS LTD. JERUSALEM BIOPARK, 2ND FLOOR JERUSALEM9112002 X Chief Executive Officer Signatures /s/ Amir Reichman 06/18/2026 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The Ordinary Shares are no par value per share, and are represented by American Depositary Shares, each of which currently represents four thousand Ordinary Shares. ( 2 )Includes 400,000,000 Ordinary Shares represented by restricted share units ("RSUs") granted on June 16, 2026, which vest in three equal annual installments thereafter, subject to the Reporting Person's continued service through such dates. ( 3 )Includes 71,637,600 Ordinary Shares represented by RSUs granted on January 25, 2024, of which 25% vested on the six-month anniversary thereof, 8.33% vested on the one-year anniversary thereof, and 66.66% vest in two equal annual installments thereafter, subject to the Reporting Person's continued service through such dates. Each RSU represents a contingent right to receive one Ordinary Share upon vesting. ( 4 )Includes 240,000,000 Ordinary Shares represented by RSUs granted on December 22, 2025, which vest in three equal annual installments thereafter, subject to the Reporting Person's continued service through such dates.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.